Navigation Links
PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
Date:1/22/2013

Cary, NC (PRWEB) January 22, 2013

Dr. Bruce Rehlaender has been appointed a Principal, Formulation Development at PharmaDirections. He will be based in the Portland, Oregon area and will have proximity to a growing market in early stage drug development. The appointment is a reflection of the invaluable contributions he has made over the past 6 years to the virtual biotech companies served by PharmaDirections.

Dr. Rehlaender joined PharmaDirections in 2007 as the Director, Formulation Development. In that capacity, he led multi-disciplinary teams of product development scientists who developed novel drug products using specialized expertise in biopharmaceutics, pharmacokinetics and formulation development.

There have been many significant achievements in his tenure, but we only have room for a few. Dr. Rehlaender led the development of the tri-layer, sustained release tablet formulations for Orexigen’s Contrave; that NDA was filed in 2010. He led many In-Silico PK Modeling programs that resulted in establishing optimum release patterns for over 12 unique client programs. He is the inventor on 5 patents that were developed for PharmaDirections’ clients was responsible for the formulation development efforts in over 20 unique client programs.

Over his 25 year industrial career, Dr. Rehlaender has developed his expertise in biopharmaceutics and formulation development with special expertise in challenges such as poorly
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
2. NSG Announces New Quartz Micro Flow Channel
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. ASAE Foundation Announces Winners of the Innovation Grant Program
6. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Wysebridge Patent Bar Review Announces the Launch of News Blog
9. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
10. BroadData Conferencing Announces Enhanced International Audio Conference Call Capabilities
11. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... groups have stepped forward in an attempt to prevent a ... the state, but outside investors are still in the picture. ... Credential), will meet with four prospective Wisconsin investors on May ... 19 in Green Bay. Those meetings will precede talks with ...
... Wis. - A technology that could enhance the ... avian influenza, and also be useful in vaccine development, ... will receive a Phase II Small Business Innovation Research ... for Allergy & Infectious Diseases. The grant will be ...
... Wis. - The president of the Wisconsin Economic ... to sign a bill that would remove from the books ... investment, but thus far the governor has been non-committal. , ... Legislature, and it has received another boost from James Otterstein, ...
Cached Biology Technology:Wisconsin investors will make their pitch to IPIC 2Pressure mounts for Doyle to repeal shareholder liability law 2
(Date:10/25/2014)... 22, 2014 A recent report, "Genetic Testing ... current and future genetic testing market. A comprehensive introduction ... covered in this report. On account of our analysis ... existing strengths and challenges; forecast for genetic testing has ... to grow at a CAGR of around 9% during ...
(Date:10/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its third quarter ended September 30, 2014. ... million, an increase of 40% compared to $4.3 million in ... quarter of 2014 was $4.1 million compared to $1.0 million ... the current three month period was primarily due to: i) ...
(Date:10/17/2014)... Accurate knowledge regarding Ebola is critical and pertinent for ... hazardous global outbreak and epidemic. The Journal, Disaster ... special issue, Ebola Virus and Public Health, to surround ... in this critical societal moment. , On October ... for Clinicians . The primer was prepared by Dr. ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... study conducted by Dr. Jesus Lovera, Assistant Professor of ... colleagues has found that the herbal supplement Ginkgo biloba ... Sclerosis (MS.) Cognitive impairment affects 40-60% of people with ... executive skills. The research findings were published online ahead ...
... recently awarded $55.5 million to university consortia to ... will advance interdisciplinary nanosystems research and education in ... years, these Nanosystems ERCs, or NERCS, will advance ... issues, such as the human health and environmental ...
... announced continued support of the Colorado BioScience Association ... sciences showcase event in Colorado to be held at ... believe in the goals and community that is fostered by ... CEO of BiOptix.   "As Colorado continues to expand its ...
Cached Biology News:LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS 2Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 2Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 3BiOptix Participates in Leading Life Sciences Event BioWest 2012 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... innovation from Magnetofection technology, SilenceMag is ... available. Simple, rapid and easy to ... non toxic. Specifically designed for siRNA ... at very low doses of siRNA.,SilenceMag ...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: